Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RPTX
stocks logo

RPTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.310
-53.73%
--
--
-0.290
-59.15%
--
--
-0.160
-58.97%
Estimates Revision
The market is revising No Change the revenue expectations for Repare Therapeutics Inc. (RPTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 31.95%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.67%
In Past 3 Month
Stock Price
Go Up
up Image
+31.95%
In Past 3 Month
Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.230
sliders
Low
3.00
Averages
3.00
High
3.00
Current: 2.230
sliders
Low
3.00
Averages
3.00
High
3.00
TD Cowen
Marc Frahm
Buy
to
Hold
downgrade
$1.82
2025-11-17
Reason
TD Cowen
Marc Frahm
Price Target
$1.82
2025-11-17
downgrade
Buy
to
Hold
Reason
TD Cowen analyst Marc Frahm downgraded Repare Therapeutics to Hold from Buy after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.
H.C. Wainwright
Buy
downgrade
$5 -> $3
2025-10-27
Reason
H.C. Wainwright
Price Target
$5 -> $3
2025-10-27
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Repare Therapeutics to $3 from $5 and keeps a Buy rating on the shares. The firm says the initial RP-1664 data "raises questions over its viability." As such, the firm removed risk-adjusted revenue forecasts for the agent.
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$10 → $5
2025-03-07
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$10 → $5
2025-03-07
Maintains
Strong Buy
Reason
Stifel
Benjamin Burnett
Strong Buy
Maintains
$9 → $4
2024-12-13
Reason
Stifel
Benjamin Burnett
Price Target
$9 → $4
2024-12-13
Maintains
Strong Buy
Reason
Stifel analyst Benjamin Burnett lowered the firm's price target on Repare Therapeutics to $4 from $9 and keeps a Buy rating on the shares after updated results for camonsertib plus lunresertib came in below expectations. The firm expects the debate after the data to focus on the likelihood of success in endometrial cancer and for continued scrutiny of the balance sheet, the analyst tells investors.
LifeSci Capital
Charles Zhu
Buy
to
Hold
Downgrades
n/a
2024-12-13
Reason
LifeSci Capital
Charles Zhu
Price Target
n/a
2024-12-13
Downgrades
Buy
to
Hold
Reason
LifeSci Capital downgraded Repare Therapeutics to Market Perform from Outperform.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Repare Therapeutics Inc (RPTX.O) is -2.48, compared to its 5-year average forward P/E of -5.51. For a more detailed relative valuation and DCF analysis to assess Repare Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.51
Current PE
-2.48
Overvalued PE
0.29
Undervalued PE
-11.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.16
Undervalued EV/EBITDA
-6.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
70.14
Current PS
0.00
Overvalued PS
196.41
Undervalued PS
-56.13
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RPTX News & Events

Events Timeline

(ET)
2025-11-14
16:58:48
Repare Therapeutics announces Q3 earnings per share of 8 cents compared to a loss of 81 cents in the previous year.
select
2025-11-14
16:50:01
XenoTherapeutics to Purchase Repare Therapeutics for $1.82 per Share Along with One Contingent Value Right
select
2025-08-08 (ET)
2025-08-08
07:35:48
Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
00:22 AMGlobenewswire
Repare Therapeutics to Receive $1.82 per Share in Sale to XenoTherapeutics
  • Shareholder Returns: Repare Therapeutics Inc. is set to receive $1.82 per share in cash from its sale to XenoTherapeutics, which is expected to provide substantial cash returns to shareholders, thereby enhancing shareholder confidence.
  • Merger Transaction: The deal will also grant Repare shareholders a non-transferable contingent value right that entitles them to additional cash payments under certain conditions, further increasing potential shareholder gains.
  • Market Reaction: As the transaction progresses, the market has shown a positive response to Repare's stock performance, indicating investor approval of the deal, which may influence future investment decisions.
  • Legal Support: Monteverde & Associates PC, acting as the representing law firm, has recovered millions for shareholders, demonstrating its strong capabilities and reputation in securities class action litigation.
[object Object]
Preview
7.0
11-29PRnewswire
TreeHouse Foods (THS) Acquired by Industrial F&B for $22.50 per Share
  • Acquisition Investigation: Halper Sadeh LLC is investigating TreeHouse Foods, Inc. (NYSE:THS) regarding its sale to Industrial F&B Investments III Inc. for $22.50 per share in cash plus a contingent value right, indicating potential breaches of fiduciary duties to shareholders.
  • Shareholder Rights Protection: The law firm encourages TreeHouse shareholders to contact them promptly to ensure their rights are enforced in the transaction, highlighting the importance of safeguarding shareholder interests.
  • Potential Legal Action: Halper Sadeh LLC may seek increased consideration for shareholders or other remedies, demonstrating a proactive approach to protecting shareholder rights in corporate transactions.
  • Legal Service Commitment: The firm offers to handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal fees, thus reducing the financial burden of pursuing their rights.
[object Object]
Preview
8.5
11-28Globenewswire
Repare Therapeutics to Receive $1.82 per Share in Sale to XenoTherapeutics
  • Transaction Details: Repare Therapeutics Inc. is set to be sold to XenoTherapeutics for an estimated cash payment of $1.82 per share, which indicates a significant valuation assessment in the merger context for shareholders.
  • Shareholder Rights: The deal includes a non-transferable contingent value right for shareholders, potentially impacting their satisfaction and confidence in the transaction, although specific conditions remain unclear.
  • Market Reaction: The market's response to this transaction is currently uncertain, and investors should monitor upcoming shareholder votes and the completion of the deal to gauge its implications for the company's future.
  • Legal Investigation: The M&A Class Action Firm is investigating the fairness of the transaction, which may influence shareholder perceptions and subsequent actions, highlighting the importance of legal compliance in mergers and acquisitions.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Repare Therapeutics Inc (RPTX) stock price today?

The current price of RPTX is 2.23 USD — it has increased 2.76 % in the last trading day.

arrow icon

What is Repare Therapeutics Inc (RPTX)'s business?

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

arrow icon

What is the price predicton of RPTX Stock?

Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Repare Therapeutics Inc (RPTX)'s revenue for the last quarter?

Repare Therapeutics Inc revenue for the last quarter amounts to 11.62M USD, decreased % YoY.

arrow icon

What is Repare Therapeutics Inc (RPTX)'s earnings per share (EPS) for the last quarter?

Repare Therapeutics Inc. EPS for the last quarter amounts to 0.08 USD, decreased -109.88 % YoY.

arrow icon

What changes have occurred in the market's expectations for Repare Therapeutics Inc (RPTX)'s fundamentals?

The market is revising No Change the revenue expectations for Repare Therapeutics Inc. (RPTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 31.95%.
arrow icon

How many employees does Repare Therapeutics Inc (RPTX). have?

Repare Therapeutics Inc (RPTX) has 129 emplpoyees as of December 05 2025.

arrow icon

What is Repare Therapeutics Inc (RPTX) market cap?

Today RPTX has the market capitalization of 95.86M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free